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Abstract Hepatocellular carcinoma (HCC) remains a
common cause of mortality worldwide. Liver transplantation
has emerged as the optimal treatment for cirrhotic patients
with HCC; however, the shortage of donor organs leaves
waitlisted patients at risk for disease progression beyond
transplant criteria. Prevention of waitlist dropout has fueled
investigation into a wide array of locoregional therapies
for the management of HCC in candidates awaiting liver
transplantation. We present a patient with HCC who
underwent treatment with sorafenib, which resulted in a
remarkable reduction in tumor burden to allow for liver
transplant listing.
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Case Report
A 54-year-old gentleman with cirrhosis and end-stage liver
disease secondary to chronic hepatitis C presented for
evaluation for liver transplantation. The patient was first
diagnosed with hepatitis C in 1990, and subsequently
diagnosed with cirrhosis in 1991 by liver biopsy. At that
time he was briefly treated with interferon, but sustained a
severe allergic reaction following his fourth dose prompting
discontinuation.InFebruaryof2007,hedevelopedworsening
fatigue and sought care from his primary care physician. A
computed tomographic (CT) scan was performed which
demonstrated a small, irregular-appearing liver consistent
with cirrhosis, but no liver masses were appreciated and the
portal venous system was patent (Fig. 1a). An alpha-
fetoprotein (AFP) level was noted to be elevated at
7,100 ng/ml in September of 2007. A CT scan was repeated
in October of 2007 and demonstrated thrombus within the
left portal vein (Fig. 1b). Magnetic resonance imaging of the
liver was performed and demonstrated cirrhosis with left
portal vein occlusion. A heterogeneous nodular mass had
replaced the entire left lobe of the liver and the caudate lobe
of the liver with evidence of increased enhancement. There
was another heterogeneous lesion with abnormally increased
signal intensity in the medial segment of the left lobe
measuring 2 cm in diameter. Both of these lesions were
highly suspicious for hepatocellular carcinoma (HCC). A
metastatic evaluation was negative and a repeat AFP level
was 24,100 ng/ml. The patient was referred to an outside
institution for transplant evaluation, and was deemed
unsuitable due to evidence of an infiltrating form of HCC
with evidence of portal vein thrombosis. By December of
2007,thepatient's AFP level had increased to 194,000 ng/ml.
A CT scan at that time demonstrated extensive thrombus
within the main portal vein near the bifurcation that extended
into the right and left portal veins. Sorafenib was started at a
dose of 400 mg twice daily in January of 2008. The AFP
level decreased to 84,800 ng/ml and continued to exhibit a
remarkable decline to 7,300 ng/ml by February of 2008, and
117 ng/ml by March of 2008. As the patient developed
leukopenia and thrombocytopenia, his sorafenib dose was
reduced to 200 mg twice daily. By April of 2008 this was
further reduced to 200 mg a day, and ultimately to 200 mg
twice weekly, on which he is currently maintained. By May
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at monthly intervals have shown a persistently low AFP
level between 3 and 5 ng/ml (Table 1).
The patient was subsequently referred to our institution
for consideration for transplantation in March of 2009. On
evaluation he reported mental slowing and difficulty with
memory, and his physical examination was significant for
ascites and peripheral edema. Laboratory testing at that
time was significant for a platelet count of 57,000, an
International Normalized Ratio of 1.4, serum albumin of
3.0, total bilirubin of 2.1, AST of 76, ALT of 68, alkaline
phosphatase of 50, and an AFP level of 3.4 ng/ml. His
calculated Model for End-Stage Liver Disease (MELD) Score
was 13. The patient underwent exploratory laparoscopy and
was found to have a grossly cirrhotic liver with no definitive
mass appreciated. Intraoperative laparoscopic ultrasound
examination of the liver did visualize an area in segment 4
that consisted of a nest of abnormal blood vessels. This area
was thoroughly biopsied, following which radiofrequency
ablation was performed due to concern for malignancy.
Notably, all of the liver biopsies demonstrated cirrhosis with
focal scar and chronic inflammation, and no evidence of
carcinoma. Follow-up imaging in October of 2009 demon-
strated a well-defined area ofperipherallow density involving
Fig. 1 CT scan of the abdomen
July 2007 demonstrating a
cirrhotic liver, and no evidence
of portal thrombus (a). Follow-
up CT scan of the abdomen
performed October 2007
demonstrating thrombus within
the left portal vein (b, arrow)
Table 1 AFP levels in a patient with HCC
Sorafenib therapy was initiated in January of 2008 (red arrow) resulting in a remarkable decrease in AFP levels, which have persisted
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corresponded to the site of prior RFA ablation. Just medial
to this ablation site was an area of more ill-defined low
density, which was suspicious for residual/recurrent tumor. A
non-occlusive thrombus involving the splenic vein, extending
to the portosplenic confluence was noted. In addition, non-
opacification of the left portal vein, with numerous associated
collaterals consistent with cavernous transformation, was
appreciated. The main portal vein and right portal vein were
patent. As the patient’s tumor burden decreased to within the
Milan criteria, and as he had demonstrated stability at that
tumor burden, the patient was subsequently listed for
transplantation with MELD exception points.
Discussion
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer mortality worldwide, with a 626,000 new
cases reported yearly [1]. The incidence of HCC remains
high in Asia and parts of Africa, but there is clear evidence
of increasing incidence in the USA and Europe, likely
related, at least in part, to an increasing incidence of
Hepatitis C infection. Although HCC can present in a
patient with a noncirrhotic liver, cirrhosis remains the main
risk factor that predisposes to the development of HCC.
Although surgical resection remains an accepted form
of therapy for noncirrhotic patients with HCC, liver
transplantation currently remains the optimal treatment
for the cirrhotic patient. Early results with liver trans-
plantation were unfavorable, plagued by poor survival
rates and a high incidence of post-transplantation
recurrence [2]. It was not until 1996, when Mazzaferro
et al. defined a subset of patients with unresectable HCC
for whom liver transplantation was the appropriate
treatment, now referred to as the “Milan criteria” [3].
Transplantation within the Milan criteria (single tumor
≤5 cm in diameter, or two to three tumors ≤3c mi n
diameter) resulted in overall and recurrence-free survival
rates of 85% and 92%, respectively, at 4 years.
Liver transplantation for HCC with tumor burden within
the Milan criteria has gained wide acceptance as a
legitimate, and optimal, treatment. The excellent results
obtained subsequently prompted further investigation into
whether the Milan criteria could be expanded to include
patients with a larger HCC tumor burden. In 2001, Yao et
al. proposed expansion of the Milan criteria for HCC liver
transplant candidates [4]. Termed the UCSF criteria, these
patients had a single tumor ≤6.5 cm in diameter, or two or
three tumors none exceeding 4.5 cm in diameter and whose
sum of tumor diameters did not exceed 8 cm. Patient
transplanted within the UCSF criteria demonstrated 1- and
5-year survival rates of 90% and 75%, respectively, results
which were equivalent when compared with survival rates
of those transplanted within the Milan criteria.
The shortage of organs, in conjunction with the risk of
HCC progression beyond the Milan criteria prompting
dropout from the liver transplant waitlist, has fueled
investigation into a wide array of locoregional therapies
for the management of HCC in candidates awaiting liver
transplantation. These therapies range from surgical resec-
tion, cryotherapy, radiofrequency ablation, percutaneous
ethanol injection, microwave ablation, interstitial laser
coagulation, and transarterial chemoembolization. Locore-
gional therapy has been proposed as a strategy to not only
retard HCC progression and prevent dropout from the
transplant waitlist, but also as a means of downstaging
patients to within Milan criteria, and thus achieve eligibility
for transplantation [5]. In addition, pre-transplant locore-
gional therapy may serve a role in improving survival
following liver transplantation for HCC [6]. Data from the
Scientific Registry of Transplant Recipients demonstrated
improved patient and graft survival rates at 3 years for
patients with HCC treated with pre-operative locoregional
therapy, when compared to untreated patients (patient
survival, 79% versus 75%, p=0.03; graft survival, 76%
versus 71%, p=0.03) [7]. The optimal form of locoregional
therapy has yet to be determined. Indeed, to achieve
complete tumor necrosis may require multiple sessions, or
even multiple forms, of locoregional therapy. Therapy not
only serves as a bridge for those patients within the Milan
criteria awaiting transplantation, but also may allow for
those patients with tumors beyond the Milan criteria to
obtain eligibility for transplantation by demonstrating a
response to locoregional therapy.
HCC is highly refractory to traditional cytotoxic chemo-
therapy, with no evidence to date of a survival benefit from
its use [8, 9]. The relatively chemo-resistant phenotype has
prompted further investigation into the use of novel small
molecule drugs for improved clinical efficacy in the
treatment of HCC. Recently, the SHARP trial, a large
randomized phase III study of patients with biopsy-proven
advanced HCC, was completed. In this study, patients were
randomized to receive either oral sorafenib or a placebo.
Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals–
Onyx Pharmaceuticals), a small molecule multi-kinase
inhibitor, acts via inhibition of tumor-cell proliferation and
tumor angiogenesis, as well as augmentation of the rate of
apoptosis. The SHARP trial was the first randomized
systemic therapy trial in patients with advanced HCC
which demonstrated an overall, albeit modest, survival
benefit. Patients receiving sorafenib, versus the placebo
group, demonstrated improvement in both overall survival
(median 10.7 months versus 7.9 months) as well as time to
progression (median 5.5 months versus 2.8 months) [10]. A
second phase III study of sorafenib versus placebo was
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strated significant improvement in overall survival (median
6.5 months versus 4.2 months) as well as progression-free
survival (median 2.8 months versus 1.4 months) in patients
treated with sorafenib versus placebo, respectively [11].
We present a remarkable case of HCC tumor response to
adjuvantsorafenibtherapy,witheffectivedownstagingtoallow
for liver transplant listing. Although there has been demonstra-
tion of improved survival in patients with unresectable HCC
treated with sorafenib, the tumor response rate of patients with
HCC treated with sorafenib has remained low (2%) [10].
However, it remains to be determined whether sorafenib, in
conjunction with locoregional therapy, can prove to be either
effective in preventing progression beyond the Milan criteria
or facilitating downstaging to within the Milan criteria, in
patients with HCC awaiting liver transplantation [12, 13].
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